Sun Pharma gets USFDA`s tentative nod for Strattera capsules
  • This Section
  • Latest
  • Web Wrap
Last Updated: Thursday, November 26, 2009, 20:33
Mumbai: Sun Pharmaceutical Industries on Thursday said it has got tentative approval from the US drug regulator for its generic product Strattera used in the treatment of mental disorders.

The US Food and Drug Administration has approved Strattera atomoxetine hydrochloride capsules, which is equivalent to drug manufacturer Eli Lilly's Strattera capsules, Sun Pharma said in a filing to the Bombay Stock Exchange (BSE).

These capsules are available in seven strengths--10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg, the Mumbai-based drug maker said.

The capsules, used in the treatment of attention deficit hyperactivity disorder, have an annual sales of nearly USD 500 million in the US.

Shares of Sun Pharma today closed at Rs 1463.25, higher by 0.78 per cent from its previous close on the BSE, whose benchmark index--Sensex--fell by 344.02 points to close at 16,854.93 points.


First Published: Thursday, November 26, 2009, 20:33

comments powered by Disqus